Cytalux
(Pafolacianine Sodium)Phase 3Small molecule
Cytalux is one of 17 small molecule programs targeting Metastatic Solid Tumors. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
41 competitors in Metastatic Solid Tumors
#DrugCompanyPhaseTrials
1Trodelvy
GileadApproved
Opdivo
Bristol-Myers SquibbPhase 2
Tagrisso
AstraZenecaPhase 2
Keytruda
Merck & Co.Phase 1
Cytalux
OOn Target Laboratories, LLC
Phase 3
Actemra
CCelltrion
Phase 1
SSGJ-612
SShenyang Sunshine Pharmaceutical Co., LTD.
Phase 2
SSGJ-705
SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
Poly ICLC
CCelldex Therapeutics
Phase 1
SSGJ-705 Combined With Chemotherapy
SShenyang Sunshine Pharmaceutical Co., LTD.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Nov 29, 2021
CYTALUX
NDA NDA214907
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pafolacianine Sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- OOn Target Laboratories, LLC